Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518167 | SCV000612524 | uncertain significance | not provided | 2018-06-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000810178 | SCV000950370 | likely benign | Episodic ataxia type 2; Developmental and epileptic encephalopathy, 42 | 2023-11-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000518167 | SCV001763876 | uncertain significance | not provided | 2024-01-04 | criteria provided, single submitter | clinical testing | Observed in a patient with absence epilepsy; however, additional variants in other genes were also identified and this variant in CACNA1A was not found in the patient's affected sibling (PMID: 31780880); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 31780880) |
Ambry Genetics | RCV002323878 | SCV002607742 | uncertain significance | Inborn genetic diseases | 2017-10-27 | criteria provided, single submitter | clinical testing | The p.R1057H variant (also known as c.3170G>A), located in coding exon 20 of the CACNA1A gene, results from a G to A substitution at nucleotide position 3170. The arginine at codon 1057 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |